Surveillance of HIV drug resistance in children receiving antiretroviral therapy: A pilot study of the world health organization's generic protocol in Maputo, Mozambique

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Vaz, P ^a   Augusto, O ^a   Bila, D ^b   MacAssa, E ^a   Vubil, A ^b   Jani, I V ^b   Pillon, R ^c   Sandstrom, P ^c   Sutherland, D ^c   Giaquinto, C ^d   Jordan, M R ^e,f   Bertagnolio, S ^e  

^a MAPUTO CENTRAL HOSPITAL   (Mozambique)

^b INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF PADOVA   (Italy)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; MAJOR CLINICAL STUDY; MALE; MOZAMBIQUE; NEWBORN; PERINATAL DRUG EXPOSURE; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS LOAD; VIRUS RESISTANCE; WORLD HEALTH ORGANIZATION;

ANTI-RETROVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT; MALE; MOZAMBIQUE; PILOT PROJECTS; PREVALENCE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 84860374254     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis006     Document Type: Article

References (34)

1. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J 2007; 26:953-6. (Pubitemid 47494171)
2. Bolton-Moore C, Cantrell RA, Chintu N, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007; 298:1888-99. (Pubitemid 350005233)
3. Sutcliffe CG, van Dijk JH, Bolton C, Persoud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8:477-89. (Pubitemid 352005822)
4. Reddi A, Grobler AC, Geddes R, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr 2007; 7:13.
5. Katabira ET, Oelrichs RB. Scaling up antiretroviral treatment in resourcelimited settings: successes and challenges. AIDS 2007; 21(Suppl 4):S5-10.
6. Janssens B, Raleigh B, Soeung S, et al. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics 2007; 120:E1134-40. (Pubitemid 350085507)
7. Fassinou P, Rouet F, Laguide R, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cô te d'Ivoire. AIDS 2004; 18:1905-13. (Pubitemid 39313206)
8. UNAIDS/WHO.Global Report on the HIV/AIDS Epidemic. Geneva, Switzerland: UNAIDS, 2011.
9. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-35. (Pubitemid 38269279)
10. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-106.
11. Vaz P, Chaix ML, Jani I, et al. Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure. Pediatr Infect Dis J 2009; 28:e283-7.
12. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1449-54.
13. Puthanakit T, Jourdain G, Hongsiriwon S, et al. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. HIV Med 2010; 11:565-72.
14. Ministry of Health. Health Mo. Inquérito Nacional de Prevalência, Riscos Comportamentais e Informacxão sobre o HIV e SIDA em Mocxambique-INSIDA 2009. Mocxambique Ministério da saú de; 2010.
15. Ministry of Health. Mocxambique MdS. Estatisticas do Programa Nacional de Controlo do HIV/SIDA. Mocxambique Ministério da saú de; 2010.
16. Ministry of Health. Saude Md. Normas de Tratamento da crinacxa infectada pelo HIV. Mocxambique Ministério da saú de; 2006.
17. Ministry of Health. Saude Md. Normas actualizadas de tratamento da criancxa infectada pelo HIV. Mocxambique Ministério da saú de; 2008.
18. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2):15-23. (Pubitemid 352019086)
19. Rhee S-Y, Gonzales MJ, Kantor R, Betts BJ, Ravela J, and Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31:298-303. (Pubitemid 36150389)
20. Jayaraman GC, Kim J, Rekart ML, et al. A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 2006; 42:86-90. (Pubitemid 43947951)
21. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4. 0. Mol Biol Evol 2007; 24:1596-9. (Pubitemid 47236692)
22. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access: recommendations for a public health approach. 2006. Available at: http://www.who.int/hiv/pub/guidelines/adult/en/index.html. Accessed 25 November 2011.
23. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. 2009. Available at: http://www.who.int/hiv/ pub/arv/advice/en/index.html. Accessed 25 November 2011.
24. Adje-Toure C, Hanson DL, Talla-Nzussouo N, et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses 2008; 24:911-7.
25. Gupta RK, Ford D, Mulenga V, et al. Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. Pediatr Infect Dis J 2010; 29:e57-62.
26. van Dijk JH, Sutcliffe CG, Munsanje B, et al. HIV-Infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy. PLoS One 2011; 6:e19006.
27. Ellis J, Molyneux EM. Experience of anti-retroviral treatment for HIVinfected children in Malawi: the 1st 12 months. Ann Trop Paediatr 2007; 27:261-7. (Pubitemid 350167611)
28. Lwembe R, Ochieng W, Panikulam A, et al. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol 2007; 79:865-72. (Pubitemid 46871541)
29. Hosseinipour MC, Weigel R, Phiri S, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-34.
30. Hunt GM, Coovadia A, Abrams EJ, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 2011; 25:1461-9.
31. Bratholm C, Johannessen A, Naman E, et al. Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital. J Antimicrob Chemother 2010; 65: 1996-2000.
32. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-22.
33. Eshleman SH, Chen S, Hudelson SE, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Di 2005; 192:30-6. (Pubitemid 40863854)
34. Coutsoudis A, Kwaan L, Thomson M. Prevention of vertical transmission of HIV-1 in resource-limited settings. Expert Rev Anti Infect Ther 2010; 8:1163-75.